Search Clinical Trials
Sponsor Condition of Interest |
---|
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After...
Children's Oncology Group
Hodgkin Lymphoma in Remission
Leukemia in Remission
Lymphoblastic Lymphoma
Osteosarcoma
Recurrent Leukemia
This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers
associated with cardiomyopathy and heart failure after cancer treatment. Studying samples
of blood in the laboratory from patients receiving dexrazoxane hydrochloride may help
doctors learn more about the effects of... expand
This clinical trial studies the effects of dexrazoxane hydrochloride on biomarkers associated with cardiomyopathy and heart failure after cancer treatment. Studying samples of blood in the laboratory from patients receiving dexrazoxane hydrochloride may help doctors learn more about the effects of dexrazoxane hydrochloride on cells. It may also help doctors understand how well patients respond to treatment. Type: Observational Start Date: Mar 2014 |
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma
Children's Oncology Group
Ganglioneuroblastoma
Localized Resectable Neuroblastoma
Localized Unresectable Neuroblastoma
Regional Neuroblastoma
Stage 4 Neuroblastoma
This research trial studies biomarkers in tumor tissue samples from patients with newly
diagnosed neuroblastoma or ganglioneuroblastoma. Studying samples of tumor tissue from
patients with cancer in the laboratory may help doctors identify and learn more about
biomarkers related to cancer. expand
This research trial studies biomarkers in tumor tissue samples from patients with newly diagnosed neuroblastoma or ganglioneuroblastoma. Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors identify and learn more about biomarkers related to cancer. Type: Observational Start Date: Nov 2000 |
Effects of Riboflavin in Mitigating Muscle Soreness in Ultra-marathon Athletes
Steven Moore
Muscle Soreness
The aim of this project is to investigate the effects of riboflavin, also known as
vitamin B2, on preventing delayed onset muscle soreness (DOMS) in ultramarathon athletes
through a randomized placebo-controlled study. expand
The aim of this project is to investigate the effects of riboflavin, also known as vitamin B2, on preventing delayed onset muscle soreness (DOMS) in ultramarathon athletes through a randomized placebo-controlled study. Type: Interventional Start Date: Jun 2023 |
Prostate Cancer IMAGing IN Early Detection (IMAGINED Trial)
The University of Texas Health Science Center at San Antonio
Prostate Cancer
The researchers hope to learn if specific types of MRI software and techniques can help
improve early prostate cancer detection at time of a MRI-guided prostate biopsy. expand
The researchers hope to learn if specific types of MRI software and techniques can help improve early prostate cancer detection at time of a MRI-guided prostate biopsy. Type: Interventional Start Date: Dec 2023 |
A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans...
National Cancer Institute (NCI)
Recurrent Langerhans Cell Histiocytosis
Refractory Langerhans Cell Histiocytosis
This phase II trial tests the safety, side effects, best dose and activity of tovorafenib
(DAY101) in treating patients with Langerhans cell histiocytosis that is growing,
spreading, or getting worse (progressive), has come back (relapsed) after previous
treatment, or does not respond to therapy (refractory).... expand
This phase II trial tests the safety, side effects, best dose and activity of tovorafenib (DAY101) in treating patients with Langerhans cell histiocytosis that is growing, spreading, or getting worse (progressive), has come back (relapsed) after previous treatment, or does not respond to therapy (refractory). Langerhans cell histiocytosis is a type of disease that occurs when the body makes too many immature Langerhans cells (a type of white blood cell). When these cells build up, they can form tumors in certain tissues and organs including bones, skin, lungs and pituitary gland and can damage them. This tumor is more common in children and young adults. DAY101 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Using DAY101 may be effective in treating patients with relapsed or refractory Langerhans cell histiocytosis. Type: Interventional Start Date: Mar 2024 |
Ketamine & Crisis Response Plan for Suicidal Ideation in the ED
The University of Texas Health Science Center at San Antonio
Suicide
The goal of this randomized pilot trial is to assess the feasibility of administering a
combination of 100mg intramuscular (IM) ketamine and Crisis Response Plan (a short
psychosocial intervention) for patients with acute suicidality in the context of the
Emergency Department setting. This study will... expand
The goal of this randomized pilot trial is to assess the feasibility of administering a combination of 100mg intramuscular (IM) ketamine and Crisis Response Plan (a short psychosocial intervention) for patients with acute suicidality in the context of the Emergency Department setting. This study will assess a combination of a pharmacologic intervention and a psychosocial one. The pharmacologic intervention is a one-time dose of 100mg ketamine delivered intramuscularly (IM) while the patient is in the ED. The psychosocial intervention under study is a brief, patient-centered therapy which takes, on average, 30 minutes to administer. Both interventions will be administered only once. The main questions this study aims to answer are: - Determine if 100mg of IM ketamine and Crisis Response Plan in combination results in greater short-term reductions in suicidal ideation in adult patients who report acutely elevated suicide risk during an ED visit. - Examine potential weight-based dose response differences in the reductions in suicidal ideation to determine if future treatment protocols with IM ketamine may benefit from weight-based dosing. Type: Interventional Start Date: Jan 2023 |
Sacituzumab Govitecan in Recurrent Glioblastoma
The University of Texas Health Science Center at San Antonio
Glioblastoma
This is an open-label single arm study. All patients will receive the investigational
agent. expand
This is an open-label single arm study. All patients will receive the investigational agent. Type: Interventional Start Date: Jan 2022 |
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
National Cancer Institute (NCI)
Low Grade Astrocytoma
Low Grade Glioma
Metastatic Low Grade Astrocytoma
Metastatic Low Grade Glioma
This phase III trial compares the effect of selumetinib versus the standard of care
treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed
or previously untreated low-grade glioma (LGG) that does not have a genetic abnormality
called BRAFV600E mutation and is not... expand
This phase III trial compares the effect of selumetinib versus the standard of care treatment with carboplatin and vincristine (CV) in treating patients with newly diagnosed or previously untreated low-grade glioma (LGG) that does not have a genetic abnormality called BRAFV600E mutation and is not associated with systemic neurofibromatosis type 1. Selumetinib works by blocking some of the enzymes needed for cell growth and may kill tumor cells. Carboplatin and vincristine are chemotherapy drugs that work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. The overall goal of this study is to see if selumetinib works just as well as the standard treatment of CV for patients with LGG. Another goal of this study is to compare the effects of selumetinib versus CV in subjects with LGG to find out which is better. Additionally, this trial will also examine if treatment with selumetinib improves the quality of life for subjects who take it. Type: Interventional Start Date: Jan 2020 |
A Study of the Drugs Selumetinib Versus Carboplatin/Vincristine in Patients With Neurofibromatosis and...
National Cancer Institute (NCI)
Low Grade Glioma
Neurofibromatosis Type 1
Visual Pathway Glioma
This phase III trial studies if selumetinib works just as well as the standard treatment
with carboplatin/vincristine (CV) for subjects with NF1-associated low grade glioma
(LGG), and to see if selumetinib is better than CV in improving vision in subjects with
LGG of the optic pathway (vision nerves).... expand
This phase III trial studies if selumetinib works just as well as the standard treatment with carboplatin/vincristine (CV) for subjects with NF1-associated low grade glioma (LGG), and to see if selumetinib is better than CV in improving vision in subjects with LGG of the optic pathway (vision nerves). Selumetinib is a drug that works by blocking some enzymes that low-grade glioma tumor cells need for their growth. This results in killing tumor cells. Drugs used as chemotherapy, such as carboplatin and vincristine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether selumetinib works better in treating patients with NF1-associated low-grade glioma compared to standard therapy with carboplatin and vincristine. Type: Interventional Start Date: Jan 2020 |
Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory...
National Cancer Institute (NCI)
Advanced Malignant Solid Neoplasm
Ann Arbor Stage III Non-Hodgkin Lymphoma
Ann Arbor Stage IV Non-Hodgkin Lymphoma
Histiocytic Sarcoma
Juvenile Xanthogranuloma
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well
treatment that is directed by genetic testing works in pediatric patients with solid
tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at
least one line of standard systemic therapy... expand
This Pediatric MATCH screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival. Genetic tests look at the unique genetic material (genes) of patients' tumor cells. Patients with genetic changes or abnormalities (mutations) may benefit more from treatment which targets their tumor's particular genetic mutation, and may help doctors plan better treatment for patients with solid tumors or non-Hodgkin lymphomas. Type: Interventional Start Date: Jul 2017 |
Ketones, SGLT2, HFrEF
The University of Texas Health Science Center at San Antonio
Type2diabetes
Heart Failure With Reduced Ejection Fraction
The study team will examine the effects of elevated plasma ketone levels following
initiation of SGLT2 inhibitor therapy in high-risk type 2 diabetes mellitus (T2DM)
individuals with heart failure (HF) with reduced ejection fraction (HFrEF) providing an
energy-rich fuel that is taken up with great... expand
The study team will examine the effects of elevated plasma ketone levels following initiation of SGLT2 inhibitor therapy in high-risk type 2 diabetes mellitus (T2DM) individuals with heart failure (HF) with reduced ejection fraction (HFrEF) providing an energy-rich fuel that is taken up with great avidity by the myocardium, to measure change in Left Ventricle diastolic and systolic function Type: Interventional Start Date: Jan 2024 |
A Study to Investigate Efficacy and Safety of OG-6219 BID in 3 Dose Levels Compared With Placebo in Participants...
Organon and Co
Endometriosis
The purpose of this global Phase 2 study is to determine the efficacy, safety, and
tolerability of 3 dose levels of OG-6219 in pre-menopausal women between 18 and 49 years
of age (inclusive), who have moderate to severe endometriosis-related pain. expand
The purpose of this global Phase 2 study is to determine the efficacy, safety, and tolerability of 3 dose levels of OG-6219 in pre-menopausal women between 18 and 49 years of age (inclusive), who have moderate to severe endometriosis-related pain. Type: Interventional Start Date: Oct 2022 |
Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy
Dennis M. McNamara, MD, MS
Peripartum Cardiomyopathy, Postpartum
The study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5
months postpartum in a randomized placebo controlled trial of bromocriptine therapy to
evaluate its impact on myocardial recovery and clinical outcomes. Given that
bromocriptine prevents breastfeeding, an additional... expand
The study will enroll 200 women newly diagnosed with peripartum cardiomyopathy within 5 months postpartum in a randomized placebo controlled trial of bromocriptine therapy to evaluate its impact on myocardial recovery and clinical outcomes. Given that bromocriptine prevents breastfeeding, an additional 50 women with peripartum cardiomyopathy excluded from the trial due to a desire to continue breastfeeding but meeting all other entry criteria will be followed in an observational cohort. Type: Interventional Start Date: Jul 2022 |
Effect of mTOR Inhibition & Other Metabolism Modulating Interventions on the Elderly [SubStudy Rapa &...
The University of Texas Health Science Center at San Antonio
Aging
The ability to mount an effective immune response declines with age, leaving the elderly
increasingly susceptible to infectious diseases and cancer. Rapamycin, an FDA approved
drug to prevent transplant rejection, increases the lifespan and healthspan of mice and
ameliorates age-related declines in... expand
The ability to mount an effective immune response declines with age, leaving the elderly increasingly susceptible to infectious diseases and cancer. Rapamycin, an FDA approved drug to prevent transplant rejection, increases the lifespan and healthspan of mice and ameliorates age-related declines in immune responsiveness, cancer survival, and cognition in laboratory animals. Investigators are conducting a translational trial to test whether rapamycin also improves life functions in humans focusing on elderly persons (aged 70-95). Substudy E will evaluate the Rapamycin and Cardiac Function. Type: Interventional Start Date: Feb 2022 |
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
Canadian Cancer Trials Group
Breast Cancer
The purpose of this study is to compare the effects on low risk breast cancer receiving
usual care that includes regional radiation therapy, with receiving no regional radiation
therapy. Researchers want to see if not giving this type of radiation treatment works as
well at preventing breast cancer... expand
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back. Type: Interventional Start Date: Oct 2018 |
Using SnapshotNIR With Provocative Leg Maneuver for PAD Assessment
Kent Imaging Inc
Peripheral Arterial Disease
The objective of this trial is to determine if Near-infrared spectroscopy (NIRS) can
accurately evaluate the degree of Peripheral Arterial Disease (PAD) during a Provocative
Elevation Maneuver of the Lower Extremity (PEMLE) test, as compared to routine clinical
assessments. expand
The objective of this trial is to determine if Near-infrared spectroscopy (NIRS) can accurately evaluate the degree of Peripheral Arterial Disease (PAD) during a Provocative Elevation Maneuver of the Lower Extremity (PEMLE) test, as compared to routine clinical assessments. Type: Observational Start Date: Jan 2024 |
SGLT2 Inhibitors, Ketones, and Cardiovascular Benefit Research Plan
The University of Texas Health Science Center at San Antonio
Type2 Diabetes
Heart Failure With Preserved Ejection Fraction
The study team will examine the effects of SGLT2i (and SGLT2i-induced increases in plasma
ketone concentrations) on skeletal muscle and cardiac ketone uptake, skeletal muscle
bioenergetics, cardiopulmonary exercise capacity, and patient-reported functional
outcomes. expand
The study team will examine the effects of SGLT2i (and SGLT2i-induced increases in plasma ketone concentrations) on skeletal muscle and cardiac ketone uptake, skeletal muscle bioenergetics, cardiopulmonary exercise capacity, and patient-reported functional outcomes. Type: Interventional Start Date: Jan 2021 |
NICU Antibiotics and Outcomes Trial
Michael Morowitz
Microbial Colonization
Extreme Prematurity
Early-Onset Neonatal Sepsis
Late-Onset Neonatal Sepsis
Necrotizing Enterocolitis of Newborn
The goal of the NANO trial is to study the longstanding clinical practice of empirically
administering intravenous antibiotics to extremely low birthweight (ELBW) infants in the
first days of life. In this 802-subject multicenter placebo-controlled randomized
clinical trial, the hypothesis to be tested... expand
The goal of the NANO trial is to study the longstanding clinical practice of empirically administering intravenous antibiotics to extremely low birthweight (ELBW) infants in the first days of life. In this 802-subject multicenter placebo-controlled randomized clinical trial, the hypothesis to be tested is that the incidence of adverse outcomes is higher in babies receiving empiric antibiotics (EA) in the first week of life compared to babies receiving placebo. The study targets a population of ELBW infants in whom the clinical decision to use or not use EA is currently most challenging -- infants that are clinically stable that did not have a known exposure to intraamniotic infection and were not born preterm for maternal indications. The primary outcome is the composite outcome of late-onset sepsis (LOS), necrotizing enterocolitis (NEC), or death during the index hospitalization. Secondary safety outcomes will include total antibiotic days, days to full enteral feedings, and common morbidities in preterm infants that have previously been linked to EA, e.g. retinopathy of prematurity and bronchopulmonary dysplasia. Weight and length z-score, and head circumference, are standard measures to be collected weekly by clinical team per a standardized protocol. Type: Interventional Start Date: Aug 2020 |
Neural Connectivity During Therapy for Adolescent PTSD
The University of Texas Health Science Center at San Antonio
PTSD
Adolescent
Psychological Trauma
Posttraumatic stress disorder in adolescence impairs neurobiological networks underlying
cognitive, social and emotional skills. Neuroimaging research that seeks to identify the
neural mechanisms of treatments for PTSD could lead to novel treatments, but progress has
been slow using current methods.... expand
Posttraumatic stress disorder in adolescence impairs neurobiological networks underlying cognitive, social and emotional skills. Neuroimaging research that seeks to identify the neural mechanisms of treatments for PTSD could lead to novel treatments, but progress has been slow using current methods. The proposed study uses an innovative approach to identify neural mechanisms of specific phases of trauma-focused therapy for youth with PTSD, allowing a new understanding of brain changes associated with the process of therapy. Type: Interventional Start Date: Nov 2022 |
Ketones, Muscle Metabolism, and SGLT2 Inhibitors - Protocol 1
The University of Texas Health Science Center at San Antonio
Heart Failure
Type 2 Diabetes Mellitus
To examine the effect of an increase in plasma beta-hydroxy-butyrate (B-OH-B) levels,
spanning the physiologic and pharmacologic range (+0.5, +2.0, and +5.0 mmol/L), on: (i)
parameters of left ventricular (LV) systolic and diastolic function utilizing cardiac
magnetic resonance imaging (MRI) and (ii)... expand
To examine the effect of an increase in plasma beta-hydroxy-butyrate (B-OH-B) levels, spanning the physiologic and pharmacologic range (+0.5, +2.0, and +5.0 mmol/L), on: (i) parameters of left ventricular (LV) systolic and diastolic function utilizing cardiac magnetic resonance imaging (MRI) and (ii) myocardial glucose uptake using positron emission tomography (PET) with 18F-fluoro-2-deoxy-D-glucose in type 2 diabetic patients with Class II-III New York Heart Association (NYHA). Type: Interventional Start Date: Jan 2019 |
Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study
SWOG Cancer Research Network
Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
Hormone Receptor-Positive Breast Carcinoma
This phase III trial compares the effect of active symptom monitoring and patient
education to patient education alone in helping young women with stage I-III breast
cancer stay on their hormone therapy medicines. The patient education tool contains
interactive weblinks which provide patients with... expand
This phase III trial compares the effect of active symptom monitoring and patient education to patient education alone in helping young women with stage I-III breast cancer stay on their hormone therapy medicines. The patient education tool contains interactive weblinks which provide patients with education material about breast cancer and side effects of therapy. Symptom monitoring is a weblink via email or text message with questions asking about symptoms. Hormone therapy for breast cancer can cause side effects, and may cause some women to stop treatment early. Asking about symptoms more often may help women keep taking hormone therapy medicines. Type: Interventional Start Date: Mar 2023 |
Palatal Donor Site Wound Healing Following Periodontal Plastic Surgery Using Amnion-Chorion Membrane
The University of Texas Health Science Center at San Antonio
Palate; Wound
The purpose of this clinical trial is to assess if donor site healing in the palatal area
and patient pain perception are similar or different when using amnio-chorion membrane
(ACM) on the donor site after surgery compared to a commonly used commercial hemostatic
agent (ActCel Cellulose Gauze). expand
The purpose of this clinical trial is to assess if donor site healing in the palatal area and patient pain perception are similar or different when using amnio-chorion membrane (ACM) on the donor site after surgery compared to a commonly used commercial hemostatic agent (ActCel Cellulose Gauze). Type: Interventional Start Date: Sep 2023 |
Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions
The University of Texas Health Science Center at San Antonio
Pheochromocytoma
Paraganglioma
Inherited Cancer Syndrome
Associated Conditions
Kidney Neoplasms
Pheochromocytomas and paragangliomas are neural crest-derived tumors of the nervous
system that are often inherited and genetically heterogeneous. Genetic screening is
recommended for patients and their relatives, and can guide clinical decisions. However,
a mutation is not found in all cases. The... expand
Pheochromocytomas and paragangliomas are neural crest-derived tumors of the nervous system that are often inherited and genetically heterogeneous. Genetic screening is recommended for patients and their relatives, and can guide clinical decisions. However, a mutation is not found in all cases. The aims of this proposal are to: 1) to map gene(s) involved in pheochromocytoma, and 2) identify genotype-phenotype correlations in patients with pheochromocytoma/paraganglioma of various genetic origins. Type: Observational [Patient Registry] Start Date: Oct 2005 |
Circulating Tumor DNA Enriched, Genomically Directed Post-neoadjuvant Trial for Patients With Residual...
Bryan Schneider, MD
Breast Cancer
Triple Negative Breast Cancer
This is a 3-arm study stratified by plasma ctDNA. Patients with residual TNBC disease
after pre-operative therapy will be assigned to 1 of 3 Arms based on plasma ctDNA
positivity and genomic marker(s). expand
This is a 3-arm study stratified by plasma ctDNA. Patients with residual TNBC disease after pre-operative therapy will be assigned to 1 of 3 Arms based on plasma ctDNA positivity and genomic marker(s). Type: Interventional Start Date: Aug 2021 |
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous...
Melanoma and Skin Cancer Trials Limited
Cutaneous Melanoma, Stage II
Patients with a primary invasive melanoma are recommended to undergo excision of the
primary lesion with a wide margin. There is evidence that less radical margins of
excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm
margin of excision of the primary lesion for... expand
Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with stage II primary invasive cutaneous melanomas (AJCC 8th edition) to determine differences in disease-free survival. A reduction in margins is expected to improve patient quality of life. Type: Interventional Start Date: Dec 2019 |
- Previous
- Next